Paul Frewer - Concepedia

Concepedia

Author

Paul Frewer

AstraZeneca (United Kingdom)ORCID

Also Known As

Frewer, Paul, P. Frewer, Paul Frewer, Paul I.H. Frewer

74

Publications

4.7K

Citations

20

H-Index

34

Concepts

All Affiliations

AstraZeneca (United Kingdom)Dana-Farber Cancer Institute National Taiwan University Hospital Institut Gustave Roussy Samsung Medical Center

PF

About

Paul Frewer is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	806
2	Health Sciences	2	2	58
3	Immunology	2	2	57
4	Cell Biology	1	1	13
5	Gastroenterology	1	1	18

Paul Frewer

×

25

Publications

4.7K

Citations

20

H-Index

	Year	Citations
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, New England Journal of Medicine	2015	2.1K
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab Marc E. Rothenberg, Amy D. Klion, Florence Roufosse, New England Journal of Medicine	2008	569
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, The Lancet Oncology	2020	406
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study Wolfgang H. Oertel, Erik Ch. Wolters, Cristina Sampaio, Movement Disorders Parkinson DiseasePharmacologyClinical TrialsDopamine AgonistNeuropharmacology	2005	208
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification Eric Van Cutsem, Yu Jeong Bang, Wasat Mansoor, Annals of Oncology Gene AmplificationGastrointestinal OncologyMedicineAdvanced Gastric AdenocarcinomaPathology	2017	183
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Judith Balmañà, Nadine Tung, Steven J. Isakoff, Annals of Oncology Breast OncologyMedicineGynecologyAdvanced BreastOther Solid Tumors	2014	175
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers Paul K. Paik, Ronglai Shen, Michael F. Berger, Clinical Cancer Research	2017	144
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i> -Amplified Non–Small Cell Lung Cancer: TATTON Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Cancer Discovery	2022	142
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor Paul A. Dickinson, Mireille Cantarini, J. Collier, Drug Metabolism and Disposition	2016	128
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, Clinical Cancer Research	2021	125

Page 1